Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
暂无分享,去创建一个
[1] R. Ljung,et al. Port‐A‐Cath usage in children with haemophilia: experience of 53 cases , 1998, Acta paediatrica.
[2] J. Avorn,et al. Prophylactic Use of Factor VIII: an Economic Evaluation , 1998, Thrombosis and Haemostasis.
[3] E. Berntorp,et al. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] J. Lusher. Prophylaxis in Children with Hemophilia: Is it the Optimal Treatment? , 1997, Thrombosis and Haemostasis.
[5] H. Pettersson,et al. Haemophilia prophylaxis in young patients–a long‐term follow‐up , 1997, Journal of internal medicine.
[6] W. Schramm,et al. Socioeconomic impact of haemophilia care: results of a pilot study , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] S. Teutsch,et al. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. , 1996, The Journal of pediatrics.
[8] E. Berntorp,et al. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations , 1996, Haemophilia : the official journal of the World Federation of Hemophilia.
[9] K. Khair,et al. The impact of prophylactic treatment on children with severe haemophilia , 1996, British journal of haematology.
[10] E. Berntorp. Methods of haemophilia care delivery: regular prophylaxis versus episodic treatment , 1995, Haemophilia : the official journal of the World Federation of Hemophilia.
[11] H. Pettersson,et al. A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs , 1994, Journal of internal medicine.
[12] M. Manco‐Johnson,et al. Results of secondary prophylaxis in children with severe hemophilia , 1994, American journal of hematology.
[13] R. Talamini,et al. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. , 1994, Seminars in hematology.
[14] H. Pettersson,et al. Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.
[15] M. Blombäck,et al. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. , 1991, The American journal of pediatric hematology/oncology.
[16] S. Rosén. Assay of factor VIII:C with a chromogenic substrate. , 2009, Scandinavian journal of haematology. Supplementum.
[17] Å. Ahlberg. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. , 1965, Acta orthopaedica Scandinavica. Supplementum.
[18] G. Kahaly. The Socioeconomic Impact , 2022 .